Key Takeaways Amarin surged 27.3% after licensing Vazkepa to Recordati for commercialization across 59 EU countries. The deal includes $25M upfront, up to$150M in milestones, and supply-based royalty revenues. AMRN expects $70M in EU cost savings over 12 months as part of a broader strategy to fuel growth.Shares of Amarin (AMRN) jumped 27.3% on Tuesday after the company announced that it has signed an exclusive long-term license and supply agreement with Italy-based Recordati to commercialize its sole ma ...